{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:10:54Z","timestamp":1747714254924,"version":"3.40.5"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec037\">\n<jats:title>Background<\/jats:title>\n<jats:p>Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-na\u00efve patients. However, comparisons in patients with an inadequate response to MTX remain unclear. This study aims to evaluate the efficacy and safety of FIL plus MTX versus FIL monotherapy in patients with rheumatoid arthritis who have an inadequate response to MTX.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec038\">\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>FAITHFUL (<jats:bold>F<\/jats:bold>ilgotinib <jats:bold>A<\/jats:bold>dd-on versus sw<jats:bold>IT<\/jats:bold>c<jats:bold>H<\/jats:bold> to <jats:bold>F<\/jats:bold>ilgotinib in patients with rhe<jats:bold>U<\/jats:bold>matoid arthritis who inadequate<jats:bold>L<\/jats:bold>y responded to methotrexate) study is a phase IV multicenter, prospective, open-label, randomized controlled trial. Patients with a history of inadequate response to at least 8 weeks of MTX and moderate or high disease activity will be assessed for eligibility at 10 centers in Japan. A history of Janus kinase inhibitor use is an exclusion criterion, but prior use of biologic agents is not considered. Enrolled patients will be randomly assigned in a 1:1 ratio to either the group adding FIL (Add-on group) or the group switching to FIL monotherapy (Switch group). The target sample size is 120 participants. The primary endpoint is the change in DAS28-CRP from baseline to week 24, aiming to assess if the Switch group is non-inferior to the Add-on group. Safety will be evaluated by assessing the incidence of adverse events.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec039\">\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The study has received approval from the Certified Review Board of Keio University Hospital (N20230002) and adheres to the principles outlined in the Declaration of Helsinki and good clinical practice standards. Prior to enrollment, all participants provide written informed consent. The findings from this study are intended to be submitted for publication in relevant peer-reviewed journals.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec040\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The trial was registered at Japan Registry of Clinical Trials (jRCTs031230673).<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0322621","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:01:23Z","timestamp":1747684883000},"page":"e0322621","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol: Filgotinib in addition to methotrexate versus filgotinib monotherapy in patients with rheumatoid arthritis with an inadequate response to methotrexate: A multicenter, prospective, open-label, randomized controlled trial (FAITHFUL Study)"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":true,"given":"Mitsuhiro","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohide","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5824","authenticated-orcid":true,"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"pone.0322621.ref001","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"JS Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0322621.ref002","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"IB McInnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0322621.ref003","first-page":"585","article-title":"Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease","volume":"16","author":"HA Fuchs","year":"1989","journal-title":"J Rheumatol"},{"issue":"1","key":"pone.0322621.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"JS Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0322621.ref005","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"R Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0322621.ref006","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"A Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0322621.ref007","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"B Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pone.0322621.ref008","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial","volume":"322","author":"MC Genovese","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"pone.0322621.ref009","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"R Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"pone.0322621.ref010","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Y Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0322621.ref011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"M Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"pone.0322621.ref012","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis","volume":"383","author":"A Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0322621.ref013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria","volume":"39","author":"AM van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0322621.ref014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"HT Maecker","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"pone.0322621.ref015","doi-asserted-by":"crossref","first-page":"651357","DOI":"10.3389\/fimmu.2021.651357","article-title":"Peripheral TIGIT+ T Follicular Helper Cells That Produce High Levels of Interleukin-21 via OX40 Represent Disease Activity in IgG4-Related Disease","volume":"12","author":"M Akiyama","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0322621.ref016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41232-025-00367-4","article-title":"CX3CR1+ age-associated CD4+ T cells contribute to synovial inflammation in late-onset rheumatoid arthritis","volume":"45","author":"M Akiyama","year":"2025","journal-title":"Inflamm Regen"},{"key":"pone.0322621.ref017","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"L Osterberg","year":"2005","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:01:27Z","timestamp":1747684887000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0322621"}},"subtitle":[],"editor":[{"given":"Masao","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0322621","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}